ACADIA PharmaceuticalsACAD +0.51%76 PB Ratio is 3.22 as of Jun. 25, 2026, which is 58% below its 10-year median of 7.62. GuruFocus rates ACAD with a GF Score™ of 76/100 and a GF Value™ of $25.02 (Fairly Valued). The stock has 8 warning signs investors should review. Among 1,233 Biotechnology companies, ACADIA Pharmaceuticals ranks worse than 55.39% on this metric.
The historical rank and industry rank for ACADIA Pharmaceuticals's PB Ratio or its related term are showing as below:
ACAD'
s PB Ratio Range Over the Past 10 Years
Min: 2.86 Med: 7.62 Max: 15.13
Current: 3.22
During the past 13 years, ACADIA Pharmaceuticals's highest PB Ratio was 15.13. The lowest was 2.86. And the median was 7.62.
ACAD's PB Ratio is ranked worse than 55.39% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs ACAD: 3.22
During the past 12 months, ACADIA Pharmaceuticals's average Book Value Per Share Growth Rate was 59.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 42.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 11.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 5.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ACADIA Pharmaceuticals was 91.30% per year. The lowest was -48.00% per year. And the median was 9.00% per year.
Back to Basics: PB Ratio
ACADIA Pharmaceuticals (NAS:ACAD) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ACADIA Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ACADIA Pharmaceuticals (ACAD) has a PB Ratio of 3.22 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ACADIA Pharmaceuticals and its competitors. This is 58% below median its historical median of 7.62. Over the past decade, ACADIA Pharmaceuticals' PB Ratio has ranged from 2.86 to 15.13. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #683 out of 1233 companies in the Biotechnology industry, placing it in the top 55.4%.
Is ACADIA Pharmaceuticals' PB Ratio too high?
ACADIA Pharmaceuticals' current PB Ratio of 3.22 is 58% below median its 10-year median of 7.62. Over the past 10 years, this metric has ranged from a low of 2.86 to a high of 15.13. The Biotechnology industry median PB Ratio is 2.80. ACADIA Pharmaceuticals' value of 3.22 is 15% above this industry median. Based on the distribution chart, ACADIA Pharmaceuticals ranks #683 out of 1233 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ACADIA Pharmaceuticals has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' PB Ratio compare to EWTX and CRNX?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #683 out of 1233 companies for PB Ratio. This places ACADIA Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.80. ACADIA Pharmaceuticals' value of 3.22 is 15% above this benchmark. Historically, ACADIA Pharmaceuticals' own PB Ratio has ranged from 2.86 to 15.13 over the past decade. While the company's 10-year median is 7.62 vs. the industry median of 2.80, ACADIA Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACADIA Pharmaceuticals's current PB Ratio of 3.22 is 15% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ACADIA Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACADIA Pharmaceuticals's current PB Ratio is 3.22, which is 58% below median its own 10-year median of 7.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (ACAD) is currently considered Fairly Valued. The stock's GF Value™ is $25.02, compared to a current price of $23.48 — trading 6.2% below its estimated fair value. The current PB Ratio is 3.22, which is 58% below median its 10-year median of 7.62 and 15% above the Biotechnology industry median of 2.80. ACADIA Pharmaceuticals' overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ACADIA Pharmaceuticals (ACAD), the current PB Ratio is 3.22 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued.
The current stock price of $23.48 is trading 6.2% below its estimated GF Value™ of $25.02.
GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.
Key valuation signals for ACAD:
PB Ratio: 3.22 (58% below median its 10-year median of 7.62)
GF Value™: $25.02 vs. price of $23.48 (6.2% below fair value)
Industry Position: 15% above the Biotechnology median (#683 of 1233)
No single metric tells the full story. See the ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
76GF Score
Get the complete analysis for ACAD
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACAD has been successfully added to your 
